How much will Ofatumumab cost after medical insurance reimburses it?

Ofatumumab (Ofatumumab) is a fully human antiCD20 monoclonal antibody. It has been marketed in China and is used to treat relapsing multiple sclerosis (RMS) in adults, including clinically isolated syndrome and relapsing-remitting form. Multiple sclerosis and active secondary progressive multiple sclerosis subsequently enter the scope of Class B medical insurance, but only adult relapsing multiple sclerosis (RMS) is reimbursed. The price may be around tens of thousands of yuan. Domestic purchase channels are difficult. The reimbursement ratio is different in different regions. The price after reimbursement may be different. For specific prices, you can ask the local medical insurance bureau and other places.